Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia
暂无分享,去创建一个
A. Alencar | A. LaCasce | S. Tyekucheva | P. Armand | M. Davids | D. Fisher | C. Jacobson | S. Ng | Jennifer R. Brown | D. Brander | J. Abramson | E. Hochberg | J. Arnason | L. Shune | R. Takvorian | M. Omaira | Chinheng Chen | James Kaminski | J. Crombie | J. Montegaard